The Tumor Immunology Program Area is composed of 34 members, spanning 14 Departments within UCLA. In the past competing cycle, investigators from this Program authored 536 publications, of which 271 (51%) were inter-programmatic and 119 (22%) intra-programmatic. 175 (33%) were placed in high-impact journals. 22 members of this Program Area used 8 out of the 8 Shared Resources that are currently funded by the JCCC. During the current funding year, peer-reviewed funding totaled $20M in total costs, including $3.6M from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the Tl Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the Tl Program Area total $1,750,995. These funds supported Interdisciplinary Grants, Seed Grants, recruitment/retention, Program Area Leadership support, funding for the use of emerging Shared Resources and trainees. Seventeen of the Program Area Members were the recipients of JCCC support. The Tumor Immunology Program Area has as its main goals: (1) to provide an optimal interactive environment to enhance the understanding of tumor immunology and (2) to develop novel immune-based clinical therapies. This program brings basic and translational scientists together into an environment that has spawned novel investigator-initiated immunotherapy clinical trials for melanoma, hepatocellular carcinoma, and brain cancers. The Tumor Immunology PA interacts with other JCCC Program Areas to facilitate immunotherapy clinical trials in lung cancer (Thoracic Oncology) and renal cell carcinoma (Genitourinary Oncology). The main areas of established intra- and inter-programmatic research include: (1) testing of dendritic cell (DC)-based vaccine approaches for cancer;(2) genetic engineering of T-lymphocytes and their precursors with T-cell receptors (TCR) to engineer a cancer-directed immune system;(3) non-invasive in vivo imaging of tumor antigenspecific T-cell in vivo distribution and tumor targeting;(4) the relationship between inflammation and cancer; (5) the use of antibody fusion proteins for cancer therapy;and (6) pharmacological strategies to sensitize cancer cells to immunotherapy. Emerging areas of highly collaborative intra-programmatic research include a broad interaction with the Thoracic Oncology and Women's Cancers Program Areas to jointly develop novel tumor immunology approaches, and the application of basic research on T-cell aging, T- regulatory (Treg) cell biology, immune transcriptional regulators, and vitamin D biology to models of tumor immunology. The basic and translational research within the Tumor Immunology Program Area uses nearly all the JCCC infrastructure and Shared Resources for its ongoing research efforts. The Flow Cytometry Shared Resource has been required for most (if not all) research projects within the Program Area. The Small Animal Imaging Shared Resource has made possible the pursuit of successful projects in T-cell imaging, projects that are now being brought from preclinical models to patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Glenn, Beth A; Hamilton, Ann S; Nonzee, Narissa J et al. (2018) Obesity, physical activity, and dietary behaviors in an ethnically-diverse sample of cancer survivors with early onset disease. J Psychosoc Oncol 36:418-436
Tsai, Wen-Ting K; Wu, Anna M (2018) Aligning physics and physiology: Engineering antibodies for radionuclide delivery. J Labelled Comp Radiopharm 61:693-714
Lisova, Ksenia; Sergeev, Maxim; Evans-Axelsson, Susan et al. (2018) Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. Nucl Med Biol 61:36-44
Chang, Yu-Ling; Rossetti, Maura; Vlamakis, Hera et al. (2018) A screen of Crohn's disease-associated microbial metabolites identifies ascorbate as a novel metabolic inhibitor of activated human T cells. Mucosal Immunol :
Jia, Qingmei; Bowen, Richard; Dillon, Barbara Jane et al. (2018) Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. Sci Rep 8:7009
Kiertscher, Sylvia M; Gangalum, Pallavi R; Ibrahim, Grace et al. (2018) A Prospective Study of Humoral and Cellular Immune Responses to Hepatitis B Vaccination in Habitual Marijuana Smokers. J Neuroimmune Pharmacol 13:219-229
Van, Christina; Condro, Michael C; Lov, Kenny et al. (2018) PACAP/PAC1 Regulation of Inflammation via Catecholaminergic Neurons in a Model of Multiple Sclerosis. J Mol Neurosci :
Leoh, Lai Sum; Kim, Yoon Kyung; Candelaria, Pierre V et al. (2018) Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. J Immunol 200:3485-3494
Hicks, Michael R; Hiserodt, Julia; Paras, Katrina et al. (2018) ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol 20:46-57
Tsang, Eric J; Wu, Benjamin; Zuk, Patricia (2018) MAPK signaling has stage-dependent osteogenic effects on human adipose-derived stem cells in vitro. Connect Tissue Res 59:129-146

Showing the most recent 10 out of 767 publications